• Tuberculosis and Respiratory Diseases
• /
• v.81 no.4
• /
• pp.339-346
• /
• 2018

Background: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a standard procedure to evaluate suspicious lymph node involvement of lung cancer because computed tomography (CT) and $^{18}F$-fluorodeoxyglucose positron emission tomography-CT (PET-CT) have limitations in their sensitivity and specificity. There are a number of benign causes of false positive lymph node such as anthracosis or anthracofibrosis, pneumoconiosis, old or active tuberculosis, interstitial lung disease, and other infectious conditions including pneumonia. The purpose of this study was to evaluate possible causes of false positive lymph node detected in chest CT or PET-CT. Methods: Two hundred forty-seven patients who were initially diagnosed with lung cancer between May 2009 and December 2012, and underwent EBUS-TBNA to confirm suspicious lymph node involvement by chest CT or PET-CT were analyzed for the study. Results: Of 247 cases, EBUS-TBNA confirmed malignancy in at least one lymph node in 189. The remaining 58 patients whose EBUS-TBNA results were negative were analyzed. Age ${\geq}65$, squamous cell carcinoma as the histologic type, and pneumoconiosis were related with false-positive lymph node involvement on imaging studies such as chest CT and PET-CT. Conclusion: These findings suggest that lung cancer staging should be done more carefully when a patient has clinically benign lymph node characteristics including older age, squamous cell carcinoma, and benign lung conditions.

• 대한핵의학회:학술대회논문집
• /
• 2001.05a
• /
• pp.66-75
• /
• 2001

Although diverse mechanisms are involved in multidrug resistance for chemotherapeutic drugs, the development of cellular P-glycoprotein(Pgp) and multidrug-resistance associated protein (MRP) are important factors in the chemotherapy failure to cancer. Various detection assays provide information about the presence of drug efflux pumps at the mRNA and protein levels. However these methods do not yield information about dynamic function of Pgp and MRP un vivo. Single photon emission tomography (SPECT) and positron emission tomography (PET) are available for the detection of Pgp and MRP-mediated transport. $^{99m}Tc$-sestaMIBl and other $^{99m}Tc$-radiopharmaceuticals are substrates for Pgp and MRP, and have been used in clinical studies for tumor imaging, and to visualize blockade of Pgp-mediated transport after modulation of Pgp pump. Colchicine, verapamil and daunorubicin labeled with $^{11}C$ have been evaluated for the quantification of Pgp-mediated transport with PET in vivo and reported to be feasible substrates with which to image Pgp function in tumors. Leukotrienes are specific substrates for MRP and N-$[^{11}C]$acetyl-leukotriene E4 provides an opportunity to study MRP function non-invasively in vivo. Results obtained from recent publications are reviewed to confirm the feasibility of using SPECT and PET to study the functionality of MDR transporters in vivo.

• Progress in Medical Physics
• /
• v.29 no.3
• /
• pp.81-91
• /
• 2018

Particulate matter (PM) in dust causes serious pathological conditions, and it has been considered a critical health issue for many years. Respiratory disorders such as bronchitis, asthma, and chronic inflammation, are the most common illnesses due to PM that appears as dust. There is evidence that cardiovascular and neurological abnormalities are caused by PM. Although an extensive amount of work has been conducted on this topic, including studies on the nature of the particles, particle size measurements, particle distribution upon inhalation, the health effects of fine particles, disease prevention, diagnosis, and treatment, to this date, there is still a considerable lack of knowledge in these areas. Therefore, the identification of the key components that cause diseases owing to PM, and the specific diagnoses of the diseases, is important. This review will explore the current literature on the origin and nature of PM and their effects on human health. In addition, it will also highlight the approaches that have been adopted in order to diagnose the effects of PM using positron emission tomography (PET) or single-photon emission computerized tomography (SPECT).

• Journal of Yeungnam Medical Science
• /
• v.26 no.1
• /
• pp.15-23
• /
• 2009

Constant technological developments in coronary artery disease have contributed to the assessment of both the presence of coronary stenosis and its hemodynamic consequences. Hence, noninvasive imaging helps guide therapeutic decisions by providing complementary information on coronary morphology and on myocardial perfusion and metabolism. This can he done using single photon emission computed tomography (SPECT) or positron emission tomography (PET) and multidetector CT (MDCT). Advances in image-processing software and the advent of SPECT/CT and PET/CT have paved the way for the combination of image datasets from different modalities, giving rise to hybrid imaging. Three dimensional cardiac hybrid imaging helped to confirm hemodynamic significance in many lesions, add new lesions such as left main coronay artery disease, exclude equivocal defects, correct the corresponding arteries to their allocated defects and identify culprit segment. Cardiac hybrid imaging avoids the mental integration of functional and morphologic images and facilitates a comprehensive interpretation of coronaty lesions and their pathophysiologic adequacy by three dimensional display of fused images, and allows the best evaluation of myocardial territories and the coronary-artery branches that serve each territory. This integration of functional and morphological information were feasible to intuitively convincing and might facilitate development of a comprehensive non-invasive assessment of coronary artery disease.

• Journal of Chest Surgery
• /
• v.32 no.4
• /
• pp.388-393
• /
• 1999

Background: Correct preoperative staging of esophageal cancer is a prerequisite for adequate treatment. We prospectively compared the accuracy of positron emission tomography (PET) with [fluorine-18]FDG in the staging of esophageal cancer to that of computed tomography (CT). Material and Method: The findings of FDG PET and of chest CT including lower neck and the upper abdomen of 20 biopsy-proven squamous cell carcinoma patients (male, 19; female, 1; mean age, 61) were compared with the pathologic findings obtained from a curative esophagectomy with lymph node dissection. Result: The sensitivities of FDG PET and CT for diagnosis of primary tumor were the same, 90.0% (18/20). Both FDG PET and CT failed to show the primary tumor in 2 of 20 patients; one had a 1cm sized carcinoma in situ and the other had T1 stage cancer. By using the results of the pathologic examinations of 193 removed lymph node groups, we calculated the diagnostic sensitivities, specificities and accuracies of PET and CT (*$\chi$2 p < 0.005). Sensitivity** Specificity Accuracy* PET 55.6%(30/54) 97.1%(135/139) 85.5%(165/193) CT 13.0%(7/54) 98.6%(137/139) 74.6%(144/193) One of four patients with a false-positive for PEThad had active pulmonary tuberculosis. Among the 24 tumor involved lymph node groups, PET failed to show tumor metastasis in 5 lymph node groups abutting the tumor and in 14 lymph node groups located where the decay correction was not performed. Conclusion: Based on the above findings, it is suggested that [F-18]FDG-PET is superior to CT in the detection of nodal metastases and in the staging of patients with esophageal cancer.

• Radioisotope journal
• /
• v.21 no.3
• /
• pp.46-60
• /
• 2006

In recent years the progress of nuclear medicine advanced dramatically in imaging and targeted radionuclide therapy is able to open op exciting perspectives as standard diagnostic and therapeutic modalities, complementing conventional modalities. Positron emission tomography/computed tomography (PET/CT) technology with FDG has been developed clinically in less than 10 years as a routine standard in oncological imaging, including a number of other fluorinated radiopharmaceuticals being evaluated for their ability to complement FDG. However, the limitation of FDG-PET such as non-specific uptake and its short half-life is not compatible with the time necessary for optimal tumour targeting. Therefore, a development of innovative positron-emitting radionuclides with half-lives longer than 10 h is needed. For therapeutic applications, the injection of higher activities is required to reach efficient adsorbed doses in radioresistant solid tumours, while limiting the irradiation of vital organs. In this application, the longer half-life of radiolsotopes are more fit well for radionuclide therapy. To achieve this, researches have to be carried in a largor spectrum of radionuclides for diagnosis and therapy. In the context of rapidly growing nuclear medicine and strong demanding innovative radionuclides, a high-energy (100 MeV), high-intensity (-mA) accelerator with proton (PEFF at KAFRI). will be operating in 2011. The priorities of PEFP will include supporting the nuclear medicine research community by providing those radionuclides with current limited availability by means of a high-energy, high-intensity accelerator.

• IEIE Transactions on Smart Processing and Computing
• /
• v.4 no.5
• /
• pp.311-317
• /
• 2015

The aim of this study is to develop a 3D registration algorithm for positron emission tomography/computed tomography (PET/CT) and magnetic resonance (MR) images acquired from independent PET/CT and MR imaging systems. Combined PET/CT images provide anatomic and functional information, and MR images have high resolution for soft tissue. With the registration technique, the strengths of each modality image can be combined to achieve higher performance in diagnosis and radiotherapy planning. The proposed method consists of two stages: normalized mutual information (NMI)-based global matching and independent component analysis (ICA)-based refinement. In global matching, the field of view of the CT and MR images are adjusted to the same size in the preprocessing step. Then, the target image is geometrically transformed, and the similarities between the two images are measured with NMI. The optimization step updates the transformation parameters to efficiently find the best matched parameter set. In the refinement stage, ICA planes from the windowed image slices are extracted and the similarity between the images is measured to determine the transformation parameters of the control points. B-spline. based freeform deformation is performed for the geometric transformation. The results show good agreement between PET/CT and MR images.

• Nuclear Medicine and Molecular Imaging
• /
• v.40 no.5
• /
• pp.275-278
• /
• 2006

We report the case of a 73-year-old man who had prostate cancer with bone metastases. Tc-99m HDP Whole body bone scan revealed multiple areas of increased bony uptake consistent with widespread bone metastases. F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) demonstrated mild F-18 FDG uptake in the lymph nodes of neck, abdomen, and pelvis. However, abnormal F-18 FDG uptake was not seen in the skeletal system. Biopsy and immunohistochemical stains of left supraclavicular mass showed metastatic prostate adenocarcinoma. Currently, there are a few reported cases of F-18 FDG PET/CT evaluation of bone metastases in prostate cancer. We discuss the discrepancy between F-18 FDG PET/CT and bone scan in the detection of osseous metastases of prostate cancer.

• Nuclear Medicine and Molecular Imaging
• /
• v.43 no.4
• /
• pp.361-362
• /
• 2009

We present a patient with high $^{18}$F-fluorodeoxyglucose (FDG) uptake detected in a neurofibroma that was confused with sarcomatous transformation on a positron emission tomography/computed tomography (PET/CT) scan. A 39-year-old male patient with a 20-year history of neurofibromatosis-1 (NF-1) performed FDG PET/CT scan for the evaluation of lesions with sarcomatous transformation. The FDG PET/CT images demonstrated varying degrees of increased FDG uptake in the multiple nodules throughout whole body. The left pelvic mass with the highest FDG uptake had a maximum standardized uptake values (maxSUV) 5.0 and surgical resection was performed. Histological analysis confirmed the presence of a benign neurofibroma infiltrated with inflammatory cells.

• Journal of the Korean Society of Radiology
• /
• v.14 no.6
• /
• pp.801-810
• /
• 2020

In this study, the health insurance application of PET and the change in the pay standard were examined, and the amount of health insurance use over the past 10 years was analyzed. Positron tomography was applied as health insurance in 2006, and after ¹⁸F-FDG was first applied as health insurance, positron tomography tests using various radioactive isotopes have been applied as health insurance. As of 2019, the number of positron emission tomography tests was 198,651 cases, and the treatment amount was about 88.3 billion won, and the number of tests according to general characteristics was higher in men than in women, and by age, the number of tests was the highest in 60s. The number of outpatient examinations was higher than that of inpatient examinations, and the number of examinations in tertiary hospitals(68.2%) was significantly higher than that of general hospitals and hospitals. As for the test site, torso test was the most common at 86.6%, and radioisotope was the most at 93.6% using ¹⁸F-FDG. The change in the use of PET for 10 years increased steadily from 2010 to 2014, but the amount of use decreased sharply afterwards as the recognition of asymptomatic long-term follow-up tests was deleted due to the government's change in health insurance application standards in 2014. As changes in health insurance standards have a great influence on changes in health insurance usage, continuous monitoring will be required in the future.